Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
In patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced liver fibrosis, does semaglutide (2.4mg subcutaneously every week) improve liver histology compared to placebo, and is it safe?
Journal: La Revue de medecine interne
Published: August 22, 2025
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.
Journal: JHEP reports : innovation in hepatology
Published: January 05, 2024
Clinical characterization of patients with primary biliary cholangitis: A report from multiple Canadian centres.
Journal: Canadian liver journal
Published: November 05, 2021
Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis.
Journal: Hepatology (Baltimore, Md.)
Published: October 10, 2021
Showing 1-5 of 5
Last Updated: 09/26/2026